The a global clinical-stage biopharmaceutical company Harbour BioMed (HBM), and contract research organization (CRO), PPD, have today announced a strategic collaboration.
As per the agreement, HBM has selected PPD as its preferred CRO partner to conduct global clinical studies. The companies have worked together previously, recently completing an Australian ethics committee (EC) submission for HBM4003, HBM’s anti-cancer immunotherapy targeting solid tumors.
“Harbour BioMed is leveraging the services of PPD Biotech, which combines the global capabilities of PPD with the hands-on approach, dedication and innovative mindset that drive the success of biotech clients,” said Anshul Thakral, executive vice president and global head of PPD Biotech.
“Harbour BioMed’s selection of PPD Biotech as its preferred partner is further evidence that pairing our unique biotech perspective with our scalable global development services is a powerful combination for our customers,” he added.
Established in late 2016, HBM’s portfolio includes five clinical-stage, in-licensed compounds as well as therapeutics generated by its internal discovery efforts. The company also has co-discovery and development collaborations in place with academic institutions and biopharmaceutical companies.
These programs leverage HMB’s two patented transgenic mouse platforms for generating fully human monoclonal antibodies (mAb), which the company also licenses out.
